<DOC>
	<DOC>NCT01920464</DOC>
	<brief_summary>this study has been request by french health authorities to evaluate the use of flixovate in infants and its place in the treatment pathway. this study has 2 main pbjectives: 1/ Evaluation of changes in the prescription share of Flixovate® compared to other topical corticosteroids (low, medium and high potency) in the population of infants aged from 3 to 12 months, from 1st January 2010 to 31st December 2012. 2/Description of the conditions of use of Flixovate® in infants aged less than 12 months (infant profile, dosage form, dosage, treatment duration, prior, concomitant and subsequent treatments etc.).</brief_summary>
	<brief_title>Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<criteria>Analysis of changes in share of prescriptions: Infants who received at least one prescription of topical steroids between 1st January 2010 and 31st December 2012. Infants aged 3 to 12 months on the day of prescription of topical steroids. Description of the conditions of use and patient profiles: Infants who received at least one prescription of topical steroids between 1st January 2010 and 31st December 2012. Infants aged 3 to 12 months on the day of prescription of topical steroids.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>